



**BlueCross
BlueShield**

Federal Employee Program.

Tecentriq (atezolizumab)

Tecentriq Hybreza* (atezolizumab and hyaluronidase-tqjs)

* Product covered on the medical benefit only time

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Stage II to IIIA non-small cell lung cancer (NSCLC)
 - a. Used as adjuvant treatment following resection and platinum-based chemotherapy
 - b. PD-L1 expression on $\geq 1\%$ of tumor cells as determined by an FDA-approved test
2. Metastatic non-small cell lung cancer (NSCLC) with **ONE** of the following:
 - a. Negative for EGFR or ALK tumor expression **AND ONE** of the following:
 - i. Disease progression on or after platinum-containing chemotherapy
 - ii. Used as first-line treatment in patients with tumors that have high PD-L1 expression as determined by an FDA-approved test
 - b. Positive EGFR or ALK tumor expression
 - i. Disease progression on or after platinum-containing chemotherapy
 - ii. Disease progression after targeted FDA-approved therapy
3. Metastatic non-squamous non-small cell lung cancer (NSCLC)
 - a. First-line treatment
 - b. Used in combination with **ONE** of the following:
 - i. Bevacizumab, paclitaxel, and carboplatin
 - ii. Paclitaxel protein-bound and carboplatin
 - c. Negative for EGFR or ALK tumor expression
4. Extensive-stage small cell lung cancer (ES-SCLC)
 - a. First-line treatment
 - b. Used in combination with carboplatin and etoposide



**BlueCross
BlueShield**

Federal Employee Program.

Tecentriq (atezolizumab)

Tecentriq Hybreza* (atezolizumab and hyaluronidase-tqjs)

* Product covered on the medical benefit only time

5. Unresectable or metastatic hepatocellular carcinoma (HCC)
 - a. Used as monotherapy or in combination with bevacizumab
 - b. Patient has not received prior systemic therapy
6. Unresectable or metastatic melanoma
 - a. Used in combination with cobimetinib and vemurafenib
 - b. Positive for BRAF V600 mutation as determined by an FDA-approved test

AND ALL of the following:

- a. Prescriber agrees to monitor liver enzymes including ALT, AST, and bilirubin
- b. Prescriber agrees to monitor for immune-related toxicities

Diagnosis

Patient must have the following:

1. Unresectable or metastatic alveolar soft part sarcoma (ASPS)
 - a. **Tecentriq only:** 2 years of age or older
 - b. **Tecentriq Hybreza only:** 18 years of age or older

AND ALL of the following:

- a. Prescriber agrees to monitor liver enzymes including ALT, AST, and bilirubin
- b. Prescriber agrees to monitor for immune-related toxicities

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic non-small cell lung cancer (NSCLC)

Tecentriq (atezolizumab)**Tecentriq Hybreza* (atezolizumab and hyaluronidase-tqjs)**

* Product covered on the medical benefit only time

2. Metastatic non-squamous non-small cell lung cancer (NSCLC)
3. Extensive-stage small cell lung cancer (ES-SCLC)
4. Unresectable or metastatic hepatocellular carcinoma (HCC)
5. Unresectable or metastatic melanoma

AND the following:

- a. **NO** disease progression or unacceptable toxicities

Diagnosis

Patient must have the following:

1. Unresectable or metastatic alveolar soft part sarcoma (ASPS)
 - a. **Tecentriq only**: 2 years of age or older
 - b. **Tecentriq Hybreza only**: 18 years of age or older

AND the following:

- a. **NO** disease progression or unacceptable toxicities

Prior - Approval *Renewal* Limits

Duration 12 months

NO renewal for Stage II to IIIA NSCLC